Research graph
References from Genetically proxied GLP1R expression does not predict exenatide response in the Exenatide-PD3 trial. Local targets link to admitted publications; unresolved targets remain external evidence.
GLP1R expression and Parkinson’s disease and related disorders in GLP-1 receptor agonist-treated type 2 diabetes
2026 · External reference
Genetic predictors of GLP1 receptor agonist weight loss and side effects
10.1038/s41586-026-10330-z · 2026 · External reference
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson’s disease in the UK: A phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial
10.1016/s0140-6736(24)02808-3 · 2025 · External reference
GLP1R gene expression and kidney disease progression
10.1001/jamanetworkopen.2024.40286 · 2024 · External reference
The genotype-tissue expression (GTEx) project
10.1038/ng.2653 · 2013 · External reference
Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials?
10.1002/sim.3639 · 2009 · External reference
Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson’s disease
10.1093/brain/awad063 · 2023 · External reference
